Nordea Investment Management AB Trims Stake in Pfizer Inc. $PFE

Nordea Investment Management AB cut its position in Pfizer Inc. (NYSE:PFE) by 20.9% in the fourth quarter, Holdings Channel reports. The firm owned 4,823,166 shares of the biopharmaceutical company’s stock after selling 1,274,180 shares during the period. Nordea Investment Management AB’s holdings in Pfizer were worth $120,073,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Alliance LLC boosted its stake in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Pfizer in the third quarter valued at $3,019,000. Money Concepts Capital Corp raised its holdings in shares of Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after buying an additional 57,188 shares during the last quarter. Vista Investment Partners LLC raised its holdings in shares of Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in shares of Pfizer during the third quarter worth about $16,613,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Price Performance

Shares of NYSE PFE opened at $26.98 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The firm has a market capitalization of $153.41 billion, a P/E ratio of 19.84 and a beta of 0.47. The company’s fifty day moving average is $26.68 and its two-hundred day moving average is $25.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm posted $0.63 EPS. The business’s revenue was down 1.2% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Bank of America lowered their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.14.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.